Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

Lancet
William J Elliott, Peter M Meyer

Abstract

The effect of different classes of antihypertensive drugs on incident diabetes mellitus is controversial because traditional meta-analyses are hindered by heterogeneity across trials and the absence of trials comparing angiotensin-converting-enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARB). We therefore undertook a network meta-analysis, which accounts for both direct and indirect comparisons to assess the effects of antihypertensive agents on incident diabetes. We undertook a systematic review up to Sept 15, 2006, and identified 48 randomised groups of 22 clinical trials with 143,153 participants who did not have diabetes at randomisation and so were eligible for inclusion in our analysis. 17 trials enrolled patients with hypertension, three enrolled high-risk patients, and one enrolled those with heart failure. The main outcome was the proportion of patients who developed diabetes. Initial drug therapy used in the trials (and the number of patients with diabetes of the total number at risk) included: an ARB (1189 of 14,185, or 8.38%), ACE inhibitor (1618 of 22,941, or 7.05%), calcium-channel blocker (CCB, 2791 of 38,607, or 7.23%), placebo (1686 of 24,767, or 6.81%), beta blocker (2705 of 35,745, or 7.57%), or...Continue Reading

References

Feb 15, 1993·Annals of Internal Medicine·J H GurwitzJ Avorn
Jan 1, 1959·Annals of Internal Medicine·R W WILKINS
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
Jun 17, 1961·JAMA : the Journal of the American Medical Association·W C HOLLIS
Feb 25, 1960·The New England Journal of Medicine·M G GOLDNERS AKGUN
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Dec 25, 2003·Diabetes Care·Raj Padwal, Andreas Laupacis
Mar 24, 2004·Hypertension·Paolo VerdecchiaCarlo Porcellati
Mar 31, 2004·Journal of Clinical Pharmacology·L Michael Prisant
Jul 17, 2004·Journal of Hypertension·Lionel H Opie, R Schall
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Dec 28, 2004·The American Journal of Cardiology·John B KostisUNKNOWN SHEP Collaborative Research Group
Feb 18, 2005·Journal of Hypertension·Karin A M Jandeleit-DahmMark E Cooper
Mar 1, 2005·Diabetes Care·Raj PadwalFinlay A McAlister
Jun 29, 2005·Circulation·Salim YusufUNKNOWN Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators
Aug 3, 2005·Current Hypertension Reports·William J Elliott
Sep 1, 2005·Circulation·Jackie BoschUNKNOWN HOPE/HOPE-TOO Study Investigators
Mar 16, 2006·The New England Journal of Medicine·Stevo JuliusUNKNOWN Trial of Preventing Hypertension (TROPHY) Study Investigators
Apr 29, 2006·Diabetes Care·Eric N TaylorGary C Curhan
Sep 19, 2006·The New England Journal of Medicine·UNKNOWN DREAM Trial InvestigatorsRury R Holman

❮ Previous
Next ❯

Citations

May 6, 2008·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Christian WernerMichael Böhm
Apr 21, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Eberhard WilleKerstin Uhl-Hochgraeber
Nov 1, 2011·Current Atherosclerosis Reports·Roderick Deano, Matthew Sorrentino
Sep 3, 2010·Current Cardiology Reports·Joel A Lardizabal, Prakash C Deedwania
Aug 10, 2007·Current Hypertension Reports·Michala E Pedersen, John R Cockcroft
Aug 10, 2007·Current Hypertension Reports·Thor TejadaBarry J Materson
Sep 9, 2008·Current Hypertension Reports·Wanpen Vongpatanasin
Jan 17, 2009·Current Hypertension Reports·Sandra J Taler
Nov 9, 2010·Current Hypertension Reports·Alan L HinderliterJames A Blumenthal
Apr 14, 2011·Current Hypertension Reports·Massimo VolpeFrancesco Paneni
Aug 1, 2012·Current Hypertension Reports·Edward RojasPeter Bolli
Mar 23, 2013·Current Hypertension Reports·César CerezoLuis M Ruilope
Dec 18, 2013·Current Hypertension Reports·Joshua I BarzilayPaul K Whelton
Mar 8, 2008·Current Treatment Options in Cardiovascular Medicine·Wai Ping Alicia ChanJohn David Horowitz
May 2, 2008·Advances in Therapy·Claudio FerriGiovambattista Desideri
Apr 3, 2012·Molecular and Cellular Endocrinology·Fei JingMasatsugu Horiuchi
Jun 12, 2012·Molecular and Cellular Endocrinology·Ranganath Muniyappa, Sahzene Yavuz
Aug 29, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Theodore W Kurtz, Uwe Klein
May 2, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masaru Iwai, Masatsugu Horiuchi
May 23, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masaru Iwai, Masatsugu Horiuchi
Nov 4, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Graziela Z Kalil, William G Haynes
Jul 19, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiromi RakugiUNKNOWN Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group
May 31, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Finlay A McAlister
Aug 22, 2012·The Pharmacogenomics Journal·J H KarnesR M Cooper-DeHoff
Aug 24, 2007·The New England Journal of Medicine·Aram V Chobanian
Aug 30, 2008·The New England Journal of Medicine·Salim YusufUNKNOWN PRoFESS Study Group
Mar 17, 2010·The New England Journal of Medicine·John J McMurrayRobert M Califf
Apr 3, 2013·Diabetes Technology & Therapeutics·Konstantinos TziomalosApostolos I Hatzitolios
Apr 14, 2009·European Heart Journal·Jan A StaessenWillem H Birkenhäger
Oct 5, 2013·European Heart Journal·Bryan Williams
Mar 20, 2013·International Journal of Epidemiology·Areti Angeliki VeronikiGeorgia Salanti
Oct 17, 2013·Pharmacogenetics and Genomics·Jason H KarnesRhonda M Cooper-Dehoff
May 26, 2010·Journal of Hypertension·James R SowersPrakash C Deedwania
Jun 26, 2010·Journal of Hypertension·Marguerite R IrvinDonna K Arnett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.